Table 2

OR for progression of radiographic sacroiliitis by at least one grade in the opinion of both readers over 2 years in patients with axial spondyloarthritis, univariate analysis

Non-radiographic axial spondyloarthritis (n=95)AS (n=94)*All patients (n=189*)
Parameters at baselineOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p Value
Sex, (male vs female)0.10 (0.01 to 0.82)0.0323.15 (0.63 to 15.73)0.1620.58 (0.24 to 1.73)0.212
HLA-B27 (positive vs negative)0.76 (0.24 to 2.45)0.6401.80 (0.21 to 15.36)0.5910.89 (0.33 to 2.38)0.809
CRP (>6 mg/l vs ≤6 mg/l)3.65 (1.19 to 11.15)0.0235.08 (1.02 to 25.38)0.0483.23 (1.37 to 7.59)0.007
ESR (>20 mm/h vs ≤20 mm/h)1.59 (0.44 to 5.72)0.4782.42 (0.64 to 9.12)0.1931.72 (0.71 to 4.17)0.233
Duration of symptoms (>5 vs ≤5 years)3.11 (0.75 to 12.87)0.1171.45 (0.62 to 3.43)0.392
Peripheral arthritis (present vs not present)0.66 (0.14 to 3.25)0.6130.67 (0.08 to 5.75)0.7120.69 (0.19 to 2.46)0.564
Uveitis ever (present vs not present)0.73 (0.15 to 3.58)0.6930.36 (0.04 to 2.98)0.3400.51 (0.15 to 1.82)0.301
Therapy with DMARD (present vs not present)0.52 (0.14 to 2.00)0.3440.20 (0.02 to 1.65)0.1340.36 (0.12 to 1.11)0.076
  • * Patients with complete ankylosis of sacroiliac joints were excluded.

  • AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HLA-B27, human leucocyte antigen B27.